References
- Azuma A. 2010. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med 4:302–20.
- Baldwin S, Bloomer J, Smith G, et al. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–70.
- Cao W, He L, Liu W, et al. 2006. Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci 833:257–9.
- Cifuentes A, Valencia J, Sanz E, et al. 1997. Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A 778:389–96.
- Sheng D, Yang O, Lin S, et al. 1998. Use of caffeine as a probe for rapid determination of cytochrome P450 CYP1A2 activity in humans. Acta Pharmacol Sin 19:44–6.
- Fahmi O, Odette A, Mary K, et al. 2010. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605–11.
- Friedrich G, Rose T, Rissler K. 2003. Determination of testosterone metabolites in human hepatocytes. I. Development of an on-line sample preparation liquid chromatography technique and mass spectroscopic detection of 6beta-hydroxytestosterone. J Chromatogr B Analyt Technol Biomed Life Sci 784:49–61.
- Giri N, Qingjian W, Yan X, et al. 2002. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23:203–11.
- He X, Luo X, Liu Z, et al. 2011. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD. Xenobiotica 41:844–50.
- Hilberg O, Simonsen U, Bendstrup E, et al. 2012. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J 6:131–43.
- Iyer N, Hyde M, Giri N. 2000. Anti-inflammatory effect of pirfenidone in the bleomycin hamster model of lung inflammation. Inflammation 24:477–91.
- Jenkins G. 2013. Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax 68:603–5.
- Ko J, Sukhova N, Thacker D, et al. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853–62.
- Lasker M, Wester R, Aramsombatdee E, et al. 1998. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16–28.
- Lehmann B, Boulieu R. 1995. Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 674:138–42.
- Lim L, Seah C, Koe X, et al. 2013. In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid. Toxicol In Vitro 27:812–24.
- Newton J, Wang W, Lu A. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–8.
- Richeldi L, Yasothan U, Kirkpatrick P. 2011. Pirfenidone. Nat Rev Drug Discov 10:489–90.
- Ogilvie BW, Zhang D, Li W, et al. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191–197.
- Spond J, Case N, Chapman RW, et al. 2003. Inhibition of experimental acute pulmonary inflammation be pirfenidone. Pulm Pham Ther 16:207–14.
- Xia L, Hong X, Sakban B, et al. 2016. Cytochrome P450 induction response in tethered spheroids as a three-dimensional human hepatocyte in vitro model. J Appl Toxicol 36:320–9.